New drug for moderate to severe lichen planus
Part of Skin clinical trials.
This study tests a new medication for people with moderate to severe lichen planus that has not improved with topical treatments. The goal is to see if it reduces symptoms and improves quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of cutaneous lichen planus (a skin condition) based on a skin biopsy.
- Your lichen planus must be moderate or severe and affect at least two body areas (such as head/neck, trunk, arms, or legs).
- Your lichen planus must not have responded to at least 3 months of topical treatment (like creams or ointments), or topical treatment is not recommended for you.
- You cannot have lichen planus caused by a drug, or a type called lichen planus pigmentosus.
- You must be willing to use an electronic diary and complete questionnaires.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cream called delgocitinib for adults with lichen sclerosus in the genital area. It aims to see if the cream can safely and effectively reduce symptoms over 52 weeks.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
This trial tests a pill called upadacitinib to see if it can reduce painful mouth sores and scalp hair loss caused by lichen planus. It may help people who have not gotten better with topical steroid creams.
This trial tests two light-based treatments (photobiomodulation and photodynamic therapy) and a steroid cream (clobetasol) for painful oral lichen planus. The goal is to see which treatment works best to reduce mouth sores and discomfort.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This study tests a new drug called LPX-TI641 to see if it's safe and how it works in people with atopic dermatitis (eczema) or psoriasis. If you have moderate-to-severe symptoms that haven't been helped by standard creams, you might be able to join.
Hear when a new Cutaneous Lichen Planus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.